使用匹莫范色林治疗帕金森病精神病的证据。
Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.
作者信息
Tampi Rajesh R, Tampi Deena J, Young Juan J, Balachandran Silpa, Hoq Rakin A, Manikkara Geetha
机构信息
Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Ohio, NH 44106, United States.
Diamond Healthcare, Richmond, VA 23219, United States.
出版信息
World J Psychiatry. 2019 Jun 10;9(3):47-54. doi: 10.5498/wjp.v9.i3.47.
The aim of this editorial is to evaluate the evidence for using pimavanserin for the treatment of Parkinson's disease psychosis (PDP) from randomized controlled trials (RCTs). We only identified two published trials that evaluated the use of pimavanserin among individuals with PDP. Both studies found that pimavanserin improved psychotic symptoms among individuals with PDP when compared to placebo. Pimavanserin was fairly well tolerated in both studies and did not appear to cause significant sedation or worsen motor symptoms among individuals with PDP. However, given the limited data, additional confirmatory studies are required before pimavanserin can be considered as a first line agent for the treatment of psychotic symptoms among individuals with PD.
这篇社论的目的是评估来自随机对照试验（RCT）中使用匹莫范色林治疗帕金森病精神病（PDP）的证据。我们仅找到两项已发表的评估匹莫范色林在PDP患者中应用的试验。两项研究均发现，与安慰剂相比，匹莫范色林可改善PDP患者的精神病性症状。在两项研究中，匹莫范色林的耐受性都相当良好，且在PDP患者中似乎不会引起明显的镇静作用或使运动症状恶化。然而，鉴于数据有限，在匹莫范色林可被视为治疗PD患者精神病性症状的一线药物之前，还需要更多的验证性研究。
Zotero 插件